Overview

CGRP-targeting drugs have changed migraine prevention more than anything in a generation. They were built specifically for migraine, they work, and most people tolerate them well. But because the molecule they block, calcitonin gene-related peptide, is also one of the most powerful blood vessel relaxers in the body, a fair question has followed these drugs since launch: if you switch CGRP off month after month, do you nudge blood pressure up?

A systematic review and meta-analysis published in Headache in June 2026 pooled 19 randomized controlled trials to answer that question directly. According to PubMed, the short version is reassuring but not the final word: across these trials, CGRP-targeting therapies were not linked to a statistically significant increase in new hypertension, with a pooled relative risk of 0.91. The catch is that the certainty of that evidence was rated very low, so the result tells us more about what short trials did not show than about what long-term real-world use will reveal.

Why Blood Pressure Is a Fair Question

To see why anyone worried about this in the first place, it helps to know what CGRP actually does outside the headache. CGRP is a 37-amino-acid neuropeptide released from sensory nerves, and it is a potent vasodilator, meaning it relaxes the smooth muscle in blood vessel walls and widens them. In the migraine world we think of CGRP as a pain and sensitization signal in the trigeminal system. In the cardiovascular world it is better known as a built-in pressure-release valve that helps protect tissue when blood flow is threatened.

That dual role sets up the concern. The CGRP-targeting migraine drugs work by removing CGRP signaling: the monoclonal antibodies either mop up the peptide itself (fremanezumab, galcanezumab, eptinezumab) or block its receptor (erenumab), and the oral gepants (rimegepant, atogepant) block the receptor as small molecules. If you take away a vasodilator, the theoretical worry is that vessels sit a little tighter and pressure drifts up, especially in people whose blood pressure is already on the edge.

This is not just armchair theory. The reason the field takes it seriously is that real safety signals showed up after these drugs reached the market, which is exactly the kind of thing short trials can miss. That backstory is worth a section of its own below.

What the Study Actually Found

The authors searched MEDLINE, Embase, and ClinicalTrials.gov through September 2024 for randomized controlled trials that compared a CGRP-targeting therapy against placebo or another treatment in adults with migraine. They pulled out new-onset hypertension as the main outcome, judged each trial's risk of bias with the Cochrane RoB 2 tool, and graded the overall certainty using GRADE. Eight publications or trial reports fed in, covering 19 underlying randomized trials.

Broken down by drug, erenumab, the receptor-blocking antibody that drew the original concern, had a relative risk of 0.71 (95% CI 0.30 to 1.70), and galcanezumab had a relative risk of 1.14 (95% CI 0.54 to 2.39). Neither reached statistical significance, and the wide confidence intervals are the real story: the data simply cannot rule out a meaningful effect in either direction yet.

The honest headline is the GRADE rating. The authors graded the certainty of the no-increased-risk finding as very low. That downgrade reflects how few hypertension events the trials recorded, the short follow-up, and the fact that the trials enrolled relatively healthy people who were screened to exclude serious cardiovascular disease. A very low certainty "no signal" is not the same as proof of safety. It means that within these short, clean trials, a signal did not surface.

"A null result in short trials of carefully selected patients is comforting, but it is not the same as a green light for everyone. The useful move is to keep a blood pressure cuff in the loop, especially in the first weeks and in anyone who already runs high." - Cerebral Torque

The Erenumab Backstory That Started This

The blood pressure question is not random. After erenumab (Aimovig) launched in 2018, the US FDA reviewed spontaneous reports submitted to its adverse event system. According to PubMed, by April 2020 there were 61 reported cases of elevated blood pressure linked to erenumab. Most were in women, the median age was 56, and 41 of the cases met regulatory criteria for a serious outcome, including seven hospitalizations. Strikingly, the blood pressure rise most often appeared within a week of the first dose, and about a third of the affected people already had a history of hypertension. On the strength of that review, hypertension was added to the Warnings and Precautions section of the erenumab label.

So the 2026 meta-analysis and the 2021 FDA signal are not in conflict. The trials say a population-level spike in hypertension did not show up under controlled conditions. The case reports say that in the wider population, some individuals do see real, sometimes serious, jumps in blood pressure, often early. The practical response that satisfies both is simple: use these drugs, and watch the cuff.

The CGRP Toolbox, Doses, and the Blood Pressure Angle

If you or your clinician are weighing one of these treatments, it helps to see the whole class in one place: how each is given, where it fits, and what is known about its cardiovascular edges. All six are recommended by the American Headache Society as first-line options for migraine prevention, meaning you no longer have to fail older drugs first.

CGRP-Targeting Preventives at a Glance

Typical preventive dosing and the current state of the blood pressure evidence for each agent. Evidence pills below grade how much randomized data speaks to the hypertension question specifically, not overall efficacy.

Who This Helps and How It Fits

It is easy to lose the forest for the cuff here, so it is worth restating why these drugs matter. In the pivotal STRIVE trial, erenumab at 70 mg or 140 mg monthly cut monthly migraine days by 3.2 and 3.7 days respectively from a baseline of about 8 days, versus 1.8 days on placebo, and roughly half of people on the 140 mg dose had at least a 50% reduction in migraine days. Older preventives borrowed from blood pressure, epilepsy, and depression medicine rarely match that combination of effect and tolerability, and people often quit them over side effects.

That is the context for any blood pressure conversation. For most people with frequent migraine attacks, the expected benefit of a CGRP-targeting preventive is large and the blood pressure risk, on current evidence, is small and manageable with monitoring. The people who deserve extra attention are not a reason to withhold the drug, they are a reason to plan:

• Existing or borderline hypertension. A third of the FDA case reports involved people with preexisting high blood pressure, so this group warrants a baseline reading and closer early follow-up.
• Established cardiovascular disease. These patients were largely excluded from the trials, which means the reassuring pooled result simply does not describe them. Decisions here are individualized.
• Older adults and postmenopausal women. The reported signal skewed toward women in their 50s, mirroring who uses these drugs, so age and sex alone are not contraindications but do support routine checks.
• Anyone starting erenumab specifically. Because it is the agent with the label warning and the earliest reported onset, the first few weeks are the window to watch.

Safety, Monitoring, and Practical Guidance

The most useful thing this body of evidence supports is a light, sensible monitoring habit rather than fear. None of the following is exotic, and all of it fits into normal migraine care.

It is worth noting that the best-known side effects of this class are not cardiovascular at all. Injection-site reactions are common across the antibodies, and constipation is a recognized issue with the receptor blockers, sometimes notable with erenumab. Blood pressure belongs on the monitoring list, but for most people it will never become an issue, and if it does, it is detectable and treatable.

Limitations Worth Keeping in View

The authors are candid about why this analysis cannot be the last word, and those limits are the difference between reading it well and overreading it.

Trials used different definitions of hypertension, which muddies any pooled count of events. They ran for months, not years, so a slow drift in pressure could be invisible. And they screened out many of the people most likely to be vulnerable, which is precisely why a clean trial result and a real-world warning can coexist. The remedy the authors call for is the right one: longer comparative studies and real-world observational data with standardized blood pressure monitoring, particularly in higher-risk groups.

The Bottom Line

Pulling it together, the picture is encouraging and grounded. CGRP-targeting therapies are genuinely effective, first-line migraine preventives, and the largest trial-level look at their blood pressure risk did not find a statistically significant increase in hypertension. At the same time, the certainty behind that reassurance is very low, real postmarketing reports of blood pressure spikes are documented for erenumab, and the trials did not study the people most likely to be at risk.

If you are doing well on one of these treatments, this study is not a reason to stop. If you are starting one, it is a good prompt to get a baseline reading and keep an eye on the cuff for the first couple of months. The reassuring trial data and the cautionary case reports point to the same calm conclusion: these are valuable drugs that pair well with a simple monitoring habit.